Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1616-2026

Philips Respironics Trilogy EV300, Software Version 1.05.15.00. Continuous home-use ventilator device. Recall

Philips Respironics Trilogy EV300, Software Version 1.05.15.00. Continuous home-use ventilator device.

FDA recall Class I

Ongoing

FDA lists this Class I recall for Philips Respironics Trilogy EV300, Software Version 1.05.15.00. Continuous home-use ventilator device.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1616-2026
Recall classification
Class I
Enforcement status
Ongoing
Initiation date
Mar 2, 2026
FDA report date
Apr 1, 2026
Quantity in commerce
113,717 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Philips Respironics Trilogy EV300, Software Version 1.05.15.00. Continuous home-use ventilator device.

The retrieved code information does not contain explicit model/GTIN pairs that this publication can reliably map.

Search FDA identifier text

Search a model, catalog, lot or UDI value exactly as printed in FDA’s product description or code information.

This search checks only the FDA product description and code information displayed on this page. It does not decode a UDI, normalize GTIN lengths or establish a relationship between separately listed codes.

FDA code information

All Model No.; All UDI; All Serial No.

View the original FDA recall notice

Why was this product recalled?

Using non-pneumatic nebulizers with Trilogy Evo Platform ventilators may result in a discrepancy between the set tidal volume and the tidal volume received by the patient.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Philips Respironics, Inc. take?

An UPDATED: "URGENT FIELD SAFETY NOTICE" dated 3/2/26 was mailed to consignees containing recall information for three different failure modes that can be experienced in all Trilogy Evo, Trilogy EVO O2, Trilogy Evo Universal, and Trilogy EV300 devices. The firm identified that using non-pneumatic nebulizers with Trilogy Evo Platform ventilators may result in a discrepancy between the set tidal volume and the tidal volume received by the patient. This can lead to under-delivery of therapy to the patient. Consignees are being instructed to update all devices with software version 1.05.15.00 through the My Philips for Professionals and In Center websites. The provided Appendix B contains the required instructions. Consignees are also instructed to review the latest version of the User Manual Addendum, communicate the safety notice to all in their organization who interact with affect devices, and forward the notice to those who received product that was further distributed. Consignees are to stop all use of non-pneumatic nebulizers, including vibrating mesh nebulizers, with all affected devices. Distributors should notify their customers of this recall with the provided notice and response form. DME and Homecare Customers can contact 1-800-345-6443 (option 2, option 1) for assistance. Hospital Customers can contact 1-800-722-9377 (option 2) for assistance.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology